War on pancreatic cancer is showing progress in worst cases

July 14, 2014

Just seven years from now, pancreatic cancer is projected to become this country's second-leading cancer killer, surpassed only by lung cancer and claiming 48,000 lives a year.

Now No. 4, pancreas cancer will climb in the ranking partly by becoming more common, but mostly because it is ferociously difficult to detect and treat, according to an analysis by the Pancreatic Cancer Action Network.

"The dramatic increase in the anticipated number of deaths ... is a wake-up call to the research and health-care systems in the United States," senior author Lynn M. Matrisian, a molecular biologist, wrote last month in the journal Cancer Research.

The hopeful counterpoint to this dire prediction is that the call has already been heard. A war on is underway, and it is improving the outlook, at least a little, for patients with the grimmest common malignancy.

The war is being driven by unconventional players who want to get new treatments into the clinic now. That includes the entertainment industry's Stand Up to Cancer initiative, family philanthropies such as the Lustgarten Foundation, the advocacy group Pancreatic Cancer Action Network (PanCan), and the PanCan-inspired federal "recalcitrant cancer" law.

The result is that medical centers across the country are testing chemotherapies, targeted therapies, immunotherapies, and much more, as they reshape the understanding and treatment of .

"We're not declaring victory. We're declaring progress," said Jeffrey A. Drebin, chair of surgery at the University of Pennsylvania's Abramson Cancer Center and a member of the SU2C "dream team."

The survival rate for cancer overall has steadily improved since war was declared in 1972. Today, 67 percent of all patients live five years, and the rate is over 90 percent for the most common cancers, breast and prostate.

In contrast, five-year survival for pancreatic cancer is 6 percent. Only one in four patients live a year. (Apple founder Steve Jobs had a neuroendocrine tumor of the pancreas, a rare and less aggressive form with a five-year survival rate of about 60 percent.)

In 2012, pancreatic cancer was diagnosed in 44,000 Americans, and killed 37,000. Lung cancer, which was responsible for more than 150,000 deaths that year, will remain the No. 1 killer by far, but last month's paper projects that pancreatic cancer will edge past colorectal, breast, and prostate for the No. 2 spot by 2021.

There are many reasons for the disparity in lethality. The pancreas - a six-inch-long flattened gland vital to digestion - lies deep in the abdomen, tough to image and access. Cancer rooted there spreads early and without symptoms. Less than 20 percent of patients are eligible for surgery, and the disease is notoriously resistant to standard chemotherapies.

So far, there is no drug that targets mutations in RAS genes, which underlie 95 percent of pancreas cancers. The genes regulate cellular signaling that controls growth, and some current therapies actually aggravate RAS-driven malignancies.

Finally, pancreatic are shrouded in - and shielded by - the stroma, a dense network of fibrous tissue, immune system cells, and scarring caused by inflammation.

Inflammation also plays a role in diabetes - which is linked to obesity, which is epidemic among Americans. Obesity and diabetes are factors behind the rising incidence of pancreatic cancer, although the connections are unclear.

The National Cancer Institute in March outlined plans to investigate the link between diabetes and pancreatic cancer, and to develop drugs that target mutated RAS genes. Both initiatives are the result of the Recalcitrant Cancer Research Act, signed into law by President Barack Obama last year, which requires the institute to step up research on cancers with low survival rates.

"We absolutely need to figure it out," said Penn oncologist Robert Vonderheide. "It's a medical emergency."

In April, Vonderheide and Johns Hopkins University oncologist Elizabeth M. Jaffee were named co-leaders of a Stand Up to Cancer team that is marshaling nine institutions and $8 million over three years to find ways to activate the immune system to effectively attack pancreatic cancer.

One promising approach supported by the entertainment industry effort involves an experimental protein being developed by Roche. It binds to immune cells that then tell macrophages - cells that gobble up cellular debris - to eat the stroma surrounding the tumor. Normally, the tumor's powerful chemical signals call in macrophages, but keep them on tight protective leashes.

"It is something of a Trojan horse approach," Vonderheide said. "The tumor is still calling in macrophages, but now we've reeducated them to attack - not promote - the tumor."

In a small study of 21 patients who got the experimental protein plus the standard chemotherapy gemcitabine, four saw their tumors temporarily shrink.

The team is also doing human tests of "step on the gas" approaches that activate T cells, the elite soldiers of the immune system, and "cut the brakes" approaches that use novel drugs to slip through immune system checkpoints.

Vonderheide's team complements the original, four-year-old Stand Up to Cancer pancreatic brigade of 28 researchers at five centers. They are working on ways to starve tumor cells by depriving them of nutrients. Pancreas tumor cells have massive energy needs, so they leach nutrients from healthy cells - one reason patients often waste away.

Albumin, a common blood protein, has turned out to be a key. Albumin serves both as a taxi, carrying molecules such as calcium around the body, and as a fuel that cells can break down for energy.

Clinical trials headed by team co-leader Daniel Von Hoff, physician in chief at the Translational Genomics Research Institute in Scottsdale, Ariz., showed a survival advantage for patients who combined gemcitabine with Abraxane, a drug that binds tiny particles of albumin to the widely used chemotherapy paclitaxel.

The advantage wasn't big; patients lived a median of 8.5 months with the two drugs, compared with 6.7 for gemcitabine alone. Folfirinox, a combination of four existing chemotherapy drugs, had a longer median survival, 11.1 months, in a study published in 2011 - although it also is far more toxic.

Still, the advantage was an inroad. With evidence that albumin helps penetrate the stroma, the team conducted mouse studies that revealed that albumin also feeds the tumor cells.

"The tumor cells suck up the albumin," said Drebin, the Penn surgeon and member of the SU2C brigade.

That, in turn, has set the stage for testing drugs that may block this intake. The team has found a ready candidate - an antimalaria drug called hydroxychloroquine.

Another pilot study is testing whether adding a vitamin D analog to the gemcitabine/Abraxane combo can inhibit inflammation and the progression of fibrosis in the stroma, a hypothesis supported by preclinical research.

Explore further: UIC conducts phase I drug study for advanced pancreatic cancer

Related Stories

UIC conducts phase I drug study for advanced pancreatic cancer

June 3, 2014
Researchers at the University of Illinois at Chicago are conducting a clinical trial to evaluate a new, three-drug combination therapy for advanced pancreatic cancer.

Now we know why drugs don't work on pancreatic cancer

June 25, 2014
The trouble with treating cancer is that each type has its own quirks. The quirks of pancreatic cancer make it one of the most lethal. The survival period after diagnosis is only four to six months. The main reason is that ...

Scientists discover new route to boost pancreatic cancer treatment

May 30, 2014
Cancer Research UK scientists have uncovered new insights into how a key pancreatic cancer drug – gemcitabine – is broken down in tumour cells, according to research* published in the British Journal of Cancer (BJC), ...

New vaccine study hopes to improve pancreatic cancer treatment

June 13, 2014
Medical investigators at the Virginia G. Piper Cancer Center at Scottsdale Healthcare are studying a new cancer immunotherapy to see if it can successfully help patients with advanced pancreatic cancer.

Starving pancreatic cancer before it has a chance to feast

June 23, 2014
(Medical Xpress)—Pancreatic cancer's low survival rate gives researchers from The University of Kansas Cancer Center even more reason to find a way to prevent and treat the hard-to-detect cancer. Drs. Snigdha Banerjee, ...

Microfluidic technology reveals potential biomarker for early pancreatic cancer

April 29, 2014
Cancer cells are on the move in the bloodstream in the very early stage of pancreatic cancer, and can be detected before cancer is diagnosed, according to research by the University of Michigan Health System.

Recommended for you

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.